biotech
biotech Articles
It is fair to ask if Illumina's stock has fallen too much on the acquisition announcement. After all, Grail could revolutionize how cancer is screened and ultimately how it is treated.
Published:
Illumina shares dipped early Monday after the company announced that it would be making a critical acquisition of Grail.
Published:
Truist Securities initiated CorMedix with a Buy rating and a $20 price target. The stock closed below $5 a share on Friday.
Published:
Precision oncology company PMV Pharmaceuticals intends to price more than 7.35 million shares for an initial public offering valued up to around $152 million.
Published:
As an approved COVID-19 vaccine nears completion in terms of clinical trials, what can we expect? In the past couple of weeks, firms working toward this goal have taken steps forward and back, which...
Published:
Gilead Sciences would not be the first company to pile on more debt to make an acquisition, but it is now eating deep into its cash for this acquisition.
Published:
Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) has announced that it will push forward with a midstage trial in the treatment of COVID-19.
Published:
Sorrento Therapeutics shares jumped on Thursday after the company announced that it received approval from the FDA for its COVID-19 treatment.
Published:
Arrowhead Pharmaceuticals has announced positive interim 24-week liver biopsy results in four subjects from its midstage study of ARO-AAT. Shares rallied on the news early Wednesday.
Published:
Last Updated:
On Tuesday, Canaccord Genuity reiterated its rating on Atara Biotherapeutics and raised its wildly bullish target price even higher.
Published:
The announcement of positive topline results in a late-stage epilepsy trial prompted a rally in Marinus Pharmaceuticals shares on Tuesday.
Published:
Companies winning approval from the FDA or beating a trial are expected in some cases. If investors already have priced this news into the stock, when it actually comes around they tend to sell the...
Published:
Cassava Sciences reported good results from a mid-stage study of its sumifilam treatment for Alzheimer's disease. Shares soared on the news.
Published:
Immunomedics shares more than doubled on Monday after the firm announced that it would be acquired by Gilead Sciences in one of the biggest deals to go down in the health care sector this year.
Published:
The August 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Published: